Market Tracker

01/16 1:05pm ET

Halozyme Therapeutics Inc (NASDAQ:HALO)

11.39
Delayed Data
As of Jan 13
 -0.47 / -3.96%
Today’s Change
6.96
Today|||52-Week Range
14.38
+15.28%
Year-to-Date
Here's Why Halozyme Therapeutics Fell as Much as 11.1% Today
Jan 10 / MotleyFool.com - Paid Partner Content
Company News for January 06, 2017
Jan 06 / Zacks.com - Paid Partner Content
Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%
Jan 10 / Zacks.com - Paid Partner Content
Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%
Jan 06 / Zacks.com - Paid Partner Content
Can the Rally in Halozyme (HALO) Shares Continue?
Jan 09 / Zacks.com - Paid Partner Content
Halozyme (HALO) Up on Positive Phase II Data on PEGPH20
Jan 06 / Zacks.com - Paid Partner Content
Why Halozyme Therapeutics, Inc Fell 40.6% in 2016
Jan 06 / MotleyFool.com - Paid Partner Content
Why Halozyme Therapeutics, Inc Is Rising Today
Jan 05 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close11.86
Today’s open11.81
Day’s range11.28 - 12.11
Volume2,193,344
Average volume (3 months)1,932,353
Market cap$1.5B
Dividend yield--
Data as of 4:00pm ET, 01/13/2017

Growth & Valuation

Earnings growth (last year)+55.36%
Earnings growth (this year)-248.35%
Earnings growth (next 5 years)+48.97%
Revenue growth (last year)+79.28%
P/E ratioNM
Price/Sales16.26
Price/Book33.95

Competitors

 Today’s
change
Today’s
% change
AVXSAveXis Inc-0.76-1.42%
FPRXFive Prime Therapeut...-1.32-2.64%
ONCESpark Therapeutics I...-0.16-0.28%
CHRSCoherus BioSciences ...+0.15+0.56%
Data as of 4:00pm ET, 01/13/2017

Financials

Next reporting dateMarch 6, 2017
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$135.1M
Annual profit (last year)-$32.2M
Net profit margin-23.86%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
--, --

Forecasts